JP2018537513A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537513A5 JP2018537513A5 JP2018531629A JP2018531629A JP2018537513A5 JP 2018537513 A5 JP2018537513 A5 JP 2018537513A5 JP 2018531629 A JP2018531629 A JP 2018531629A JP 2018531629 A JP2018531629 A JP 2018531629A JP 2018537513 A5 JP2018537513 A5 JP 2018537513A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- hepe
- pharmaceutically acceptable
- use according
- configuration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- -1 complex Chemical class 0.000 claims description 4
- 230000004761 fibrosis Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 206010022489 Insulin Resistance Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 210000001789 adipocyte Anatomy 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 125000004494 ethyl ester group Chemical group 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 125000004492 methyl ester group Chemical group 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 239000000902 placebo Substances 0.000 claims description 2
- 229940068196 placebo Drugs 0.000 claims description 2
- 125000005457 triglyceride group Chemical group 0.000 claims description 2
- OWFVSJHRFRIEAK-UHFFFAOYSA-N 15-hydroxyicosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCC(O)CCCC=CC=CC=CC=CC=CC(O)=O OWFVSJHRFRIEAK-UHFFFAOYSA-N 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 1
- WLKCSMCLEKGITB-XWJJKCKWSA-N 15-HEPE Chemical compound CC\C=C/CC(O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-XWJJKCKWSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 239000002253 acid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562269280P | 2015-12-18 | 2015-12-18 | |
| US62/269,280 | 2015-12-18 | ||
| PCT/IB2016/001878 WO2017103671A1 (en) | 2015-12-18 | 2016-12-19 | Compositions comprising 15-hepe and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019214063A Division JP2020063259A (ja) | 2015-12-18 | 2019-11-27 | １５−ｈｅｐｅを含む組成物及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018537513A JP2018537513A (ja) | 2018-12-20 |
| JP2018537513A5 true JP2018537513A5 (enExample) | 2019-09-19 |
Family
ID=57995240
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531629A Pending JP2018537513A (ja) | 2015-12-18 | 2016-12-19 | １５−ｈｅｐｅを含む組成物及びその使用方法 |
| JP2019214063A Pending JP2020063259A (ja) | 2015-12-18 | 2019-11-27 | １５−ｈｅｐｅを含む組成物及びその使用方法 |
| JP2021118532A Pending JP2021178840A (ja) | 2015-12-18 | 2021-07-19 | １５−ｈｅｐｅを含む組成物及びその使用方法 |
| JP2023118782A Pending JP2023153863A (ja) | 2015-12-18 | 2023-07-21 | １５－ｈｅｐｅを含む組成物及びその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019214063A Pending JP2020063259A (ja) | 2015-12-18 | 2019-11-27 | １５−ｈｅｐｅを含む組成物及びその使用方法 |
| JP2021118532A Pending JP2021178840A (ja) | 2015-12-18 | 2021-07-19 | １５−ｈｅｐｅを含む組成物及びその使用方法 |
| JP2023118782A Pending JP2023153863A (ja) | 2015-12-18 | 2023-07-21 | １５－ｈｅｐｅを含む組成物及びその使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US9855238B2 (enExample) |
| EP (2) | EP3389647B1 (enExample) |
| JP (4) | JP2018537513A (enExample) |
| KR (6) | KR20220038818A (enExample) |
| CN (2) | CN113230244A (enExample) |
| AR (1) | AR107143A1 (enExample) |
| AU (4) | AU2016370626B2 (enExample) |
| BR (1) | BR122023026625A2 (enExample) |
| CA (2) | CA3008774C (enExample) |
| ES (1) | ES2948444T3 (enExample) |
| IL (3) | IL318963A (enExample) |
| MX (2) | MX394051B (enExample) |
| NZ (1) | NZ744323A (enExample) |
| PH (1) | PH12018501279A1 (enExample) |
| RU (2) | RU2737089C2 (enExample) |
| SG (1) | SG11201805149XA (enExample) |
| WO (1) | WO2017103671A1 (enExample) |
| ZA (2) | ZA201804779B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| US10017453B2 (en) | 2013-11-15 | 2018-07-10 | Ds Biopharma Limited | Pharmaceutically acceptable salts of fatty acids |
| MA41120A (fr) | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| MA47141A (fr) | 2015-05-13 | 2019-11-06 | Ds Biopharma Ltd | Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation |
| US20170020836A1 (en) | 2015-07-21 | 2017-01-26 | Dignity Sciences Limited | Compositions Comprising 15-HEPE and Methods of Treating or Preventing Cancer and Neurologic Disease |
| RU2737089C2 (ru) * | 2015-12-18 | 2020-11-24 | Эфиммьюн Лимитед | Композиции, содержащие 15-hepe, и способы их применения |
| CN113116878A (zh) * | 2020-01-10 | 2021-07-16 | 南京大学 | 15s-hepe用于增强t细胞介导的肿瘤免疫治疗的新用途 |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
| US11622495B2 (en) | 2021-06-01 | 2023-04-11 | Gint Co., Ltd. | Method of automatically combining farm vehicle and work machine and farm vehicle |
| CN113855659B (zh) * | 2021-11-24 | 2022-12-23 | 中国人民解放军东部战区总医院 | 12-hepe或其药学上可接受的脂肪酸改善精子发生障碍的应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05186342A (ja) * | 1992-01-10 | 1993-07-27 | Fujirebio Inc | 免疫調節作用を併せもつ抗炎症剤 |
| GB9301446D0 (en) | 1993-01-26 | 1993-03-17 | Scotia Holdings Plc | Internal radiation damage |
| AU683027B2 (en) | 1993-01-27 | 1997-10-30 | Scotia Holdings Plc | Triglycerides |
| AU702240B2 (en) | 1993-10-01 | 1999-02-18 | R.P. Scherer Corporation | Methods and compositions for dispensing fragrances |
| GB9715444D0 (en) | 1997-07-22 | 1997-09-24 | Scotia Holdings Plc | Therapeutic and dietary compositions |
| JP2000191525A (ja) | 1998-12-25 | 2000-07-11 | Nof Corp | 皮膚外用剤組成物 |
| EP1762557B1 (en) | 2000-02-16 | 2011-04-06 | The Brigham And Women's Hospital, Inc. | Aspirin-triggered lipid mediators |
| US20020188024A1 (en) | 2000-08-23 | 2002-12-12 | Chilton Floyd H. | Fatty acid-containing emulsion with increased bioavailability |
| US20040043013A1 (en) | 2000-12-28 | 2004-03-04 | Mccleary Edward Larry | Metabolic uncoupling therapy |
| CN1268328C (zh) | 2001-05-30 | 2006-08-09 | 拉克斯戴尔有限公司 | 辅酶q与二十碳五烯酸(epa) |
| NZ540154A (en) | 2002-11-22 | 2008-07-31 | Nippon Suisan Kaisha Ltd | External composition containing polyunsaturated fatty acid or its salt or ester |
| JP2005179211A (ja) | 2003-12-17 | 2005-07-07 | Idemitsu Kosan Co Ltd | 皮膚外用剤組成物 |
| US20070105954A1 (en) | 2003-12-31 | 2007-05-10 | Ingennus Limited | Formulation containing a carboxylic acid or an ester thereof |
| WO2005102309A2 (en) | 2004-04-26 | 2005-11-03 | Ltb4 Sweden Ab | In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration |
| CN101043884A (zh) | 2004-07-01 | 2007-09-26 | 谢彭斯眼科研究公司 | 用于治疗眼部疾病和病症的组合物和方法 |
| US7666447B2 (en) | 2004-10-08 | 2010-02-23 | Pharmanutrients | Compositions including Krill extracts and conjugated linoleic acid and methods of using same |
| US7893106B2 (en) | 2004-11-19 | 2011-02-22 | Martek Biosciences, Corporation | Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same |
| JP5504405B2 (ja) * | 2005-06-10 | 2014-05-28 | 国立大学法人山口大学 | 血管病予防に効果を有する食品組成物 |
| EP3285072B1 (en) | 2006-08-08 | 2020-04-15 | Metabolon, Inc. | Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof |
| GB0802116D0 (en) | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| US20110105510A1 (en) | 2008-06-17 | 2011-05-05 | Hiroshi Ishikawa | Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis |
| JP2010229099A (ja) * | 2009-03-27 | 2010-10-14 | Mochida Pharmaceut Co Ltd | 脂質異常症の改善または治療薬 |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| US8618168B2 (en) * | 2009-05-22 | 2013-12-31 | Mochida Pharmaceutical Co., Ltd. | Self-emulsifying composition of OMEGA3 fatty acid |
| CA2690488C (en) | 2010-01-19 | 2013-06-11 | Accucaps Industries Limited | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof |
| US10154977B2 (en) | 2011-03-25 | 2018-12-18 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory particles |
| US20120264824A1 (en) | 2011-04-15 | 2012-10-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| EP2768496A1 (en) | 2011-10-19 | 2014-08-27 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof |
| AU2012345942A1 (en) | 2011-11-29 | 2014-06-12 | Dignity Sciences Limited | Compositions comprising 20-carbon fatty acids and methods of making and using same |
| LT2800563T (lt) | 2012-01-06 | 2018-10-25 | Omthera Pharmaceuticals Inc. | Laisvos rūgšties formos omega-3 polinesočiųjų riebalų rūgščių dpa praturtintos kompozicijos |
| US20120264705A1 (en) | 2012-01-26 | 2012-10-18 | Dignity Sciences Limited | Antimicrobial compositions comprising 15-hetre and methods of use thereof |
| US20130267598A1 (en) | 2012-02-23 | 2013-10-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same |
| AU2013240427B2 (en) * | 2012-03-30 | 2017-08-03 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions |
| DK2833740T3 (da) | 2012-04-04 | 2017-01-02 | Pronova Biopharma Norge As | Sammensætninger omfattende omega-3-fedtsyrer og D-vitamin til acne vulgaris og/eller eksem og fremgangsmåder og anvendelser deraf |
| ES2946109T3 (es) * | 2012-05-10 | 2023-07-12 | Solutex Na Llc | Aceites con actividad antiinflamatoria que contienen mediadores pro-resolutivos especializados naturales y sus precursores |
| GB201213484D0 (en) * | 2012-07-30 | 2012-09-12 | Dignity Sciences Ltd | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same |
| GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| KR102275447B1 (ko) * | 2013-07-18 | 2021-07-08 | 모치다 세이야쿠 가부시키가이샤 | ω3 지방산의 자기 유화 조성물 |
| US10017453B2 (en) * | 2013-11-15 | 2018-07-10 | Ds Biopharma Limited | Pharmaceutically acceptable salts of fatty acids |
| AU2015204531B2 (en) * | 2014-01-10 | 2019-11-14 | Afimmune Limited | Pharmaceutical compositions comprising 15-HEPE and methods of treating asthma and lung disorders using same |
| MA41120A (fr) | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| CN113893240A (zh) * | 2015-01-16 | 2022-01-07 | 艾菲穆恩有限公司 | 包含15-hepe的组合物和其使用方法 |
| MA47141A (fr) * | 2015-05-13 | 2019-11-06 | Ds Biopharma Ltd | Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation |
| US20170020836A1 (en) * | 2015-07-21 | 2017-01-26 | Dignity Sciences Limited | Compositions Comprising 15-HEPE and Methods of Treating or Preventing Cancer and Neurologic Disease |
| RU2737089C2 (ru) | 2015-12-18 | 2020-11-24 | Эфиммьюн Лимитед | Композиции, содержащие 15-hepe, и способы их применения |
-
2016
- 2016-12-19 RU RU2018126361A patent/RU2737089C2/ru active
- 2016-12-19 CN CN202110567290.8A patent/CN113230244A/zh active Pending
- 2016-12-19 BR BR122023026625-0A patent/BR122023026625A2/pt not_active Application Discontinuation
- 2016-12-19 EP EP16834282.2A patent/EP3389647B1/en active Active
- 2016-12-19 CN CN201680082030.9A patent/CN108697680A/zh active Pending
- 2016-12-19 US US15/383,889 patent/US9855238B2/en active Active
- 2016-12-19 JP JP2018531629A patent/JP2018537513A/ja active Pending
- 2016-12-19 EP EP23158607.4A patent/EP4218736A3/en active Pending
- 2016-12-19 MX MX2021000773A patent/MX394051B/es unknown
- 2016-12-19 MX MX2018007390A patent/MX379262B/es unknown
- 2016-12-19 KR KR1020227008483A patent/KR20220038818A/ko not_active Ceased
- 2016-12-19 KR KR1020257027779A patent/KR20250130433A/ko active Pending
- 2016-12-19 AU AU2016370626A patent/AU2016370626B2/en active Active
- 2016-12-19 AR ARP160103915A patent/AR107143A1/es not_active Application Discontinuation
- 2016-12-19 IL IL318963A patent/IL318963A/en unknown
- 2016-12-19 KR KR1020187020457A patent/KR20180094516A/ko not_active Ceased
- 2016-12-19 IL IL294736A patent/IL294736A/en unknown
- 2016-12-19 KR KR1020247011532A patent/KR20240052856A/ko not_active Ceased
- 2016-12-19 ES ES16834282T patent/ES2948444T3/es active Active
- 2016-12-19 SG SG11201805149XA patent/SG11201805149XA/en unknown
- 2016-12-19 RU RU2020137883A patent/RU2020137883A/ru unknown
- 2016-12-19 KR KR1020207013456A patent/KR20200055154A/ko not_active Ceased
- 2016-12-19 CA CA3008774A patent/CA3008774C/en active Active
- 2016-12-19 KR KR1020237010220A patent/KR20230047501A/ko not_active Ceased
- 2016-12-19 NZ NZ744323A patent/NZ744323A/en unknown
- 2016-12-19 WO PCT/IB2016/001878 patent/WO2017103671A1/en not_active Ceased
- 2016-12-19 CA CA3129008A patent/CA3129008A1/en active Pending
-
2017
- 2017-12-14 US US15/841,363 patent/US10231945B2/en active Active
-
2018
- 2018-06-06 IL IL259846A patent/IL259846A/en unknown
- 2018-06-14 PH PH12018501279A patent/PH12018501279A1/en unknown
- 2018-07-17 ZA ZA2018/04779A patent/ZA201804779B/en unknown
-
2019
- 2019-01-31 US US16/263,486 patent/US20190224154A1/en not_active Abandoned
- 2019-11-27 JP JP2019214063A patent/JP2020063259A/ja active Pending
-
2020
- 2020-11-11 AU AU2020267224A patent/AU2020267224B2/en active Active
-
2021
- 2021-07-15 ZA ZA2021/04969A patent/ZA202104969B/en unknown
- 2021-07-19 JP JP2021118532A patent/JP2021178840A/ja active Pending
-
2022
- 2022-05-20 US US17/750,262 patent/US12274685B2/en active Active
- 2022-12-23 AU AU2022291628A patent/AU2022291628B2/en active Active
-
2023
- 2023-07-21 JP JP2023118782A patent/JP2023153863A/ja active Pending
-
2025
- 2025-03-05 AU AU2025201593A patent/AU2025201593A1/en active Pending
- 2025-03-19 US US19/083,602 patent/US20250281442A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537513A5 (enExample) | ||
| RU2020137883A (ru) | Композиции, содержащие 15-hepe, и способы их применения | |
| ES2683355T3 (es) | Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades | |
| JP2019048843A5 (enExample) | ||
| JP5927236B2 (ja) | 乾癬を予防または低減する方法 | |
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| JP2018517774A5 (enExample) | ||
| HK1206264A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2013544887A5 (enExample) | ||
| JP2017222722A5 (enExample) | ||
| HK1199726A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2015503593A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| TR201816176T4 (tr) | Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler. | |
| JP2019516739A5 (enExample) | ||
| JP2015500223A5 (enExample) | ||
| HK1198619A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2020534270A5 (enExample) | ||
| JP2018502163A5 (enExample) | ||
| RU2020123900A (ru) | Новые соединения, ингибирующие mtor | |
| RU2020123899A (ru) | Новые соединения, ингибирующие mtor | |
| JP2020533296A5 (enExample) | ||
| JP2017536380A (ja) | １５−ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 | |
| WO2015047982A3 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2016537432A5 (enExample) |